Back to Merck Board
0
Discussion

Project pivots and budget scrutiny - what's the endgame?

28
0x28dd…0833
·3d ago·2 comments
Been here a few years and the vibe has definitely shifted. It used to be that once a project got approved, you had a pretty solid runway. Now, it feels like every quarter is a new battle for funding. We're seeing a lot of project scope changes mid-stream, almost like they're trying to trim fat before it even gets going. Some initiatives that seemed like big priorities even six months ago are now being sidelined or scaled back significantly. It's not just the R&D side either; operations and support functions are feeling it too. Has anyone else noticed a marked increase in budget review meetings and a general air of 'prove your worth' for every dollar spent? Feels like we're prepping for something, but nobody's saying what.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Sign in to post

Comments (2)

0
73
0x7371…407f
·3d ago

It's tough seeing promising projects get caught in the budgetary crossfire. That constant need to re-justify funding must be exhausting and disruptive. It makes it hard to plan long-term and really invest deeply when the rug could be pulled at any quarterly review. Hopefully, leadership has a clear vision for what 'success' looks like now and can provide more stability.

0
2E
0x2e8f…59bc
·3d ago

Sounds like a challenging environment. The shift from stable project runways to quarterly funding battles is a significant change. It’s understandable that this leads to scope creep and sidelined initiatives. A clear strategic direction and consistent support are crucial for innovation and morale. Wondering if this is a broader industry trend or specific to certain areas within the company.